US 11,993,597 B2
Inhibitors of KRAS G12C and methods of using the same
Brian Alan Lanman, Woodland Hills, CA (US); Shon Booker, Sherman Oaks, CA (US); Clifford Goodman, Calabasas, CA (US); Anthony B. Reed, Newbury Park, CA (US); Jonathan D. Low, Northridge, CA (US); Hui-Ling Wang, Thousand Oaks, CA (US); Ning Chen, Thousand Oaks, CA (US); Ana Elena Minatti, Santa Monica, CA (US); Ryan Wurz, Newbury Park, CA (US); and Victor J. Cee, Thousand Oaks, CA (US)
Assigned to Amgen Inc., Thousand Oaks, CA (US)
Filed by Amgen Inc., Thousand Oaks, CA (US)
Filed on Mar. 10, 2022, as Appl. No. 17/692,026.
Application 17/692,026 is a continuation of application No. 16/817,109, filed on Mar. 12, 2020, granted, now 11,306,087.
Application 16/817,109 is a continuation of application No. 16/125,359, filed on Sep. 7, 2018, granted, now 10,640,504, issued on May 5, 2020.
Claims priority of provisional application 62/556,223, filed on Sep. 8, 2017.
Prior Publication US 2022/0213101 A1, Jul. 7, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61K 31/519 (2006.01); A61P 35/00 (2006.01); A61K 31/7068 (2006.01); A61K 38/07 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 31/519 (2013.01); A61P 35/00 (2018.01); A61K 31/7068 (2013.01); A61K 38/07 (2013.01); A61K 2300/00 (2013.01)] 50 Claims
 
1. A compound having a structure of formula (I)

OG Complex Work Unit Chemistry
wherein
A is independently N or CH;
W is independently N or CH;
wherein one or both of A and W is N;
R1 and R2 are independently a branched or a linear —C1—C6 alkyl, wherein the —C1-C6 alkyl is substituted with one or more of independently selected from halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, nitro, cyano, alkylamino, —C1—C8 alkyl, —C2—C8 alkenyl, —C2—C8 alkynyl, —NC, amino, —CO2H, —CO2C1—C8_alkyl, —OOOC1—C8_alkyl, cycloalkyl, —C3—C10 heterocycloalkyl, —C5—C10 aryl, and —C5—C10 heteroaryl;
R3is phenyl substituted by 1 or 2 R5 substituents;
R5 is independently selected from one or more halo, —OH, or NH2;
R4 is halo; or
a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, or a pharmaceutically acceptable salt of the atropisomer thereof.